Bliss Gvs Pharma Ltd vs Brooks Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Bliss GVS Pharma Ltd is ₹ 267.45 as of 06 May 15:30 . The P/E Ratio of Bliss GVS Pharma Ltd changed from 14.9 on March 2021 to 14.7 on March 2025 . This represents a CAGR of -0.27% over 5 yearsThe P/E Ratio of Brooks Laboratories Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Bliss GVS Pharma Ltd changed from ₹ 1018 crore on March 2021 to ₹ 1238 crore on March 2025 . This represents a CAGR of 4.00% over 5 yearsThe Market Cap of Brooks Laboratories Ltd changed from ₹ 153.53 crore on March 2021 to ₹ 317.37 crore on March 2025 . This represents a CAGR of 15.63% over 5 years The revenue of Bliss GVS Pharma Ltd for the Dec '25 is ₹ 236.71 crore as compare to the Sep '25 revenue of ₹ 252.86 crore. This represent the decline of -6.39% The revenue of Brooks Laboratories Ltd for the Dec '25 is ₹ 21.89 crore as compare to the Sep '25 revenue of ₹ 29.58 crore. This represent the decline of -26% The ebitda of Bliss GVS Pharma Ltd for the Dec '25 is ₹ 50.73 crore as compare to the Sep '25 ebitda of ₹ 51.94 crore. This represent the decline of -2.33% The ebitda of Brooks Laboratories Ltd for the Dec '25 is ₹ 6.05 crore as compare to the Sep '25 ebitda of ₹ 8.65 crore. This represent the decline of -30.06% The net profit of Bliss GVS Pharma Ltd changed from ₹ 22.11 crore to ₹ 24.78 crore over 7 quarters. This represents a CAGR of 6.73% The net profit of Brooks Laboratories Ltd changed from ₹ -2.41 crore to ₹ 5.5 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Bliss GVS Pharma Ltd changed from 7.64 % on March 2021 to 7.64 % on March 2025 . This represents a CAGR of 0.00% over 5 yearsThe Dividend Payout of Brooks Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Bliss GVS Pharma Ltd

Bliss GVS Pharma Limited was originally incorporated as a Private Limited Company in the name of Bliss Chemicals & Pharmaceuticals India Private Limited in 1984.
The status converted into a Public Limited Company and the name of the Company was changed to Bliss Chemicals & Pharmaceuticals India Limited and further to Bliss GVS Pharma Limited on May 12, 2006. The Company is engaged in manufacturing, marketing, trading and export of pharmaceutical products.
The Company has its manufacturing facility at Palghar which is WHO GMP approved.
The business operates five cutting-edge production facilities that adhere to WHO-GMP, EU-MP, ISO 14001 and OHSAS 45001 standards. The company commenced its business in 1985.
In 1994 the company introduced a new pharmaceutical product VAGID. During the financial year ended 31 March 2014, Bliss GVS Pharma's R&D center, received approval from Government of India's Department for Scientific & Industrial Research (DSIR).

About Brooks Laboratories Ltd

Brooks Laboratories Limited was incorporated on January 23, 2002.
The company was initially promoted for manufacturing latest molecules in Injectables, tablets and dry syrups for the domestic customers.
The Company is a pharmaceutical manufacturing company working on contract basis and have its own marketing team to cater the critical care segment.
It offer a variety of dosage from Beta lactam Tablets, Beta lactam Dry Syrup, General Injections, Liquid Injections, Dry Powder Injections, and Eye/Ear Drops, Oncology Products, Hormonal Injections etc. The company's manufacturing facilities are designed to manufacture a variety of products in the formulation segment using a combination of processes.
At Baddi, they manufacture wide range of products under the formulation segment for various top notch companies of India.

FAQs for the comparison of Bliss GVS Pharma Ltd and Brooks Laboratories Ltd

Which company has a larger market capitalization, Bliss GVS Pharma Ltd or Brooks Laboratories Ltd?

Market cap of Bliss GVS Pharma Ltd is 2,829 Cr while Market cap of Brooks Laboratories Ltd is 166 Cr

What are the key factors driving the stock performance of Bliss GVS Pharma Ltd and Brooks Laboratories Ltd?

The stock performance of Bliss GVS Pharma Ltd and Brooks Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bliss GVS Pharma Ltd and Brooks Laboratories Ltd?

As of May 6, 2026, the Bliss GVS Pharma Ltd stock price is INR ₹267.45. On the other hand, Brooks Laboratories Ltd stock price is INR ₹56.38.

How do dividend payouts of Bliss GVS Pharma Ltd and Brooks Laboratories Ltd compare?

To compare the dividend payouts of Bliss GVS Pharma Ltd and Brooks Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.